Edible mushrooms as emerging biofactories for natural therapeutics and oral biopharmaceutical delivery

Abstract

Mushrooms have long served as both food and medicine, providing polysaccharides, terpenoids, phenolics, and peptides with diverse health benefits. Extensive studies have begun to clarify the molecular mechanisms underlying these therapeutic effects, which include anti-aging, immunomodulatory, anticancer, and anti-inflammatory activities. Translational research is progressing from preclinical models to clinical trials, reinforcing the biomedical potential of mushroom-derived compounds. Advances in fungal genetic modification and gene editing have further positioned edible mushrooms as promising platforms for recombinant biopharmaceutical production. Their eukaryotic protein-processing capacity, natural bioencapsulation, and GRAS (Generally Recognized as Safe) status make them well-suited for sustainable and orally deliverable therapeutics. Engineered mushrooms show strong potential as platforms for oral vaccines and recombinant protein production, bridging traditional medicinal use with modern molecular farming.